MarketCapExport financials
Allied Healthcare Products (AHPI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Allied Healthcare Products Financial Ratios 2022-2008 | AHPI
Brief overview of Allied Healthcare Products's valuation multiples
Ratios are assessed across five available annual reports in the 2015–2020 interval.
The current valuation set is EV/EBITDA 12.52x (median 13.15x), P/S 0.89x (median 0.91x), P/B 0.27x (median 0.52x). The current ratio basket stands about 17.7% below the five-year comparison base. Earnings and risk trends should explain the discount.
The latest available business-quality ratios are ROE -37%, ROA -9.8%, ROCE -24.2%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash conversion cycle increased 21.2 days to 271.1 days, weakening working-capital efficiency.
Valuation takeaway
Allied Healthcare Products's discount may reflect genuine profitability issues rather than market inefficiency alone.
Annual Financial Ratios Allied Healthcare Products
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.8 | -20.1 | 27.9 | -3.2 | -9.4 | -22.0 | -21.4 | -12.7 | -656.4 | -40.9 | -91117.8 | 2396.9 | - | - | - | |
P/S |
0.9 | 3.4 | 1.8 | 0.7 | 0.9 | 1.0 | 1.0 | 0.3 | 0.8 | 1.0 | 1.0 | 1.2 | - | - | - |
EPS |
-0.5 | -0.3 | 0.2 | -0.4 | -0.2 | -0.1 | -0.1 | -0.2 | -0.0 | -0.1 | -0.1 | 0.0 | 0.0 | - | - |
EV (Enterprise Value) |
2.06 M | 22.6 M | 16.9 M | 8.26 M | 10.5 M | 10.8 M | 11.2 M | 11.2 M | 31.7 M | 37.1 M | 42 M | 53.2 M | -5.26 M | -1.94 M | -6.15 M |
EBITDA per Share |
-0.2 | -0.14 | 0.34 | -0.17 | 0.04 | 0.21 | 0.21 | 0.16 | 0.16 | 0.05 | 0.16 | 0.17 | 0.2 | - | - |
EV/EBITDA |
-2.5 | -41.1 | 12.5 | -12.0 | 62.2 | 12.8 | 13.1 | 18.0 | 25.4 | 89.7 | 32.8 | 37.9 | -3.3 | - | - |
PEG |
0.01 | 0.1 | -0.16 | 0.03 | -0.28 | -0.6 | -0.61 | -0.49 | 0.05 | 0.07 | 0.18 | 1.11 | - | - | - |
P/B |
0.3 | 1.3 | 1.0 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 1.3 | 1.5 | 1.6 | 2.0 | - | - | - |
P/CF |
-1.3 | -6.2 | 30.2 | 82.5 | -8.5 | -12.2 | -33.9 | 19.3 | -7.1 | 1815.6 | 43.5 | 37.3 | - | - | - |
ROE % |
-36.97 | -10.98 | 7.88 | -12.88 | -5.57 | -2.35 | -2.05 | -3.43 | -0.20 | -3.55 | -0.00 | 0.08 | 0.44 | - | - |
ROA % |
-9.84 | -6.56 | 3.56 | -9.91 | -4.50 | -1.94 | -1.67 | -2.84 | -0.17 | -3.06 | -0.00 | 0.07 | - | - | - |
ROCE % |
-24.19 | -10.68 | 8.27 | -12.72 | -5.44 | -1.51 | -2.04 | -3.32 | -0.16 | -3.52 | -0.00 | 0.15 | 0.78 | - | - |
Current Ratio |
- | - | - | 4.3 | 5.2 | 5.7 | 4.6 | 5.8 | 7.4 | 7.3 | 6.9 | 6.9 | - | - | - |
DSO |
160.8 | 161.8 | 103.0 | 172.6 | 160.1 | 156.1 | 169.3 | 37.5 | 39.8 | 43.5 | 43.4 | 20.9 | - | - | - |
DIO |
133.4 | 115.0 | 112.7 | 105.1 | 109.2 | 117.7 | 115.3 | 119.5 | 117.7 | 116.4 | 112.0 | 53.8 | - | - | - |
DPO |
23.1 | 30.3 | 30.6 | 20.4 | 19.5 | 22.4 | 20.6 | 15.7 | 15.0 | 18.8 | 18.8 | 8.4 | - | - | - |
Operating Cycle |
294.2 | 276.8 | 215.8 | 277.6 | 269.3 | 273.8 | 284.6 | 157.0 | 157.6 | 160.0 | 155.5 | 74.8 | - | - | - |
Cash Conversion Cycle |
271.1 | 246.5 | 185.2 | 257.3 | 249.8 | 251.4 | 263.9 | 141.4 | 142.6 | 141.2 | 136.7 | 66.4 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Allied Healthcare Products
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.32 | - | -0.32 | -0.29 | -0.1 | -0.29 | -0.25 | 0.17 | -0.08 | -0.38 | -0.04 | -0.38 | 0.09 | -0.19 | -0.31 | -0.19 | -0.22 | -0.09 | -0.19 | -0.09 | -0.1 | -0.09 | 0.1 | -0.09 | -0.1 | -0.09 | 0.07 | -0.18 | -0.06 | -0.01 | -0.09 | -0.01 | -0.12 | -0.11 | -0.07 | -0.11 | -0.03 | -0.06 | -0.05 | -0.06 | -0.02 | -0.06 | -0.02 | - | -0.02 | - | 0.01 |
EBITDA per Share |
- | -0.22 | - | -0.31 | -0.28 | 0.02 | -0.22 | -0.21 | 0.18 | 0.04 | -0.3 | 0.01 | -0.38 | 0.07 | -0.08 | -0.25 | -0.19 | -0.05 | 0.06 | -0.13 | -0.06 | 0.11 | 0.05 | -0.07 | -0.09 | 0.02 | -0.01 | -0.04 | -0.17 | 0.06 | 0.08 | -0.05 | - | -0.05 | -0.03 | -0.07 | -0.11 | -0.07 | -0.01 | -0.04 | - | 0.09 | 0.08 | 0.01 | 0.01 | 0.01 | 0.08 | 0.01 |
ROE % |
-49.49 | -54.07 | -36.21 | -49.97 | -42.36 | -21.17 | -20.09 | -22.04 | -13.55 | -36.69 | -30.12 | -20.91 | -28.82 | -19.62 | -29.05 | -25.08 | -20.38 | -16.41 | -12.46 | -12.12 | -11.82 | -11.48 | -13.29 | -14.76 | -12.73 | -14.20 | -12.34 | -8.89 | -9.49 | -6.03 | -7.90 | -11.46 | -10.60 | -14.17 | -11.03 | -9.08 | -8.25 | -4.48 | -3.93 | -2.02 | -1.00 | -0.91 | -0.90 | -0.90 | -0.90 | -0.54 | 0.08 | -0.53 |
ROA % |
-23.15 | -25.44 | -17.52 | -24.82 | -22.65 | -11.86 | -11.63 | -14.37 | -9.39 | -22.92 | -18.56 | -13.10 | -19.53 | -14.06 | -21.29 | -18.75 | -15.49 | -12.95 | -9.98 | -9.75 | -9.49 | -9.25 | -10.51 | -11.65 | -10.08 | -11.22 | -9.96 | -7.21 | -7.77 | -5.02 | -6.57 | -9.56 | -8.87 | -11.85 | -9.28 | -7.68 | -6.99 | -3.83 | -3.34 | -1.71 | -0.85 | -0.77 | -0.76 | -0.76 | -0.77 | -0.45 | 0.07 | -0.46 |
ROCE % |
-47.77 | -51.99 | -34.80 | -48.18 | -40.90 | -19.74 | -18.75 | -20.89 | -12.52 | -35.82 | -35.44 | -26.28 | -34.33 | -25.18 | -28.60 | -23.87 | -19.24 | -14.50 | -10.64 | -11.20 | -10.91 | -11.47 | -13.16 | -14.53 | -13.02 | -14.39 | -12.59 | -9.19 | -9.22 | -5.83 | -7.72 | -11.30 | -11.59 | -15.17 | -14.75 | -13.93 | -12.95 | -9.21 | -6.28 | -3.21 | -1.55 | -1.40 | -1.38 | -1.38 | -1.38 | -0.84 | 0.15 | -0.84 |
DSO |
- | 17.4 | - | 33.3 | 37.1 | 31.8 | 36.8 | 42.2 | 30.2 | 37.0 | 38.8 | 27.8 | 39.7 | 37.5 | 37.3 | 41.5 | 40.2 | 45.9 | 39.4 | 37.8 | 36.7 | 38.8 | 17.8 | 34.5 | 40.9 | 42.5 | 40.1 | 39.3 | 38.5 | 37.9 | 35.3 | 36.9 | 36.2 | 38.0 | 36.1 | 36.7 | 36.1 | 36.6 | 37.8 | 38.0 | 35298.4 | 40951.6 | 43.0 | 46.0 | 40.0 | 42.1 | 45.9 | - |
DIO |
- | 61.3 | - | 123.5 | 137.7 | 128.6 | 132.3 | 136.1 | 91.6 | 100.3 | 143.5 | 102.9 | 117.8 | 108.1 | 110.3 | 119.2 | 109.3 | 110.4 | 122.2 | 127.2 | 118.8 | 116.4 | 124.3 | 118.7 | 124.2 | 114.7 | 118.3 | 123.6 | 119.3 | 127.4 | 128.0 | 120.4 | 132.8 | 128.5 | 138.8 | 136.0 | 135.4 | 119.8 | 119.0 | 127.3 | 119.0 | 116.6 | 125.3 | 110.8 | 125.3 | 108.1 | 121.2 | - |
DPO |
- | 19.8 | - | 29.5 | 24.2 | 22.6 | 24.9 | 35.7 | 25.5 | 25.1 | 41.2 | 29.5 | 28.5 | 25.1 | 25.9 | 27.9 | 23.3 | 23.5 | 24.4 | 25.4 | 23.8 | 18.9 | 22.0 | 21.0 | 26.6 | 28.1 | 22.9 | 24.0 | 21.8 | 17.5 | 18.3 | 17.2 | 20.5 | 22.0 | 22.7 | 22.2 | 20.1 | 18.2 | 20.6 | 22.0 | 19.2 | 19.7 | 22.0 | 19.4 | 22.0 | 17.5 | 18.9 | - |
Operating Cycle |
- | - | - | 156.8 | 169.2 | 168.1 | 39.5 | 178.0 | 144.1 | 139.3 | 112.4 | 137.4 | 151.8 | 136.1 | 151.7 | 142.8 | 147.6 | 160.6 | 145.7 | 160.4 | 158.9 | 162.4 | 132.5 | 156.4 | 160.1 | 158.4 | 168.4 | 161.4 | 155.8 | 162.6 | 155.5 | 163.8 | 162.6 | 156.6 | 163.1 | 161.9 | 176.0 | 169.7 | 169.2 | 168.1 | 33483.3 | 42754.9 | 161.9 | 176.1 | 165.3 | 150.2 | 167.0 | - |
Cash Conversion Cycle |
- | - | - | 127.4 | 144.3 | 140.6 | 39.5 | 143.5 | 108.9 | 104.1 | 87.5 | 112.2 | 125.3 | 115.4 | 129.2 | 120.0 | 121.7 | 135.6 | 126.2 | 135.0 | 134.4 | 141.4 | 113.2 | 136.8 | 138.1 | 134.1 | 142.5 | 135.9 | 132.8 | 142.7 | 137.9 | 146.4 | 144.3 | 140.3 | 148.9 | 144.6 | 153.3 | 149.9 | 151.6 | 148.3 | 33462.7 | 42732.2 | 140.9 | 152.2 | 143.3 | 132.8 | 148.1 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Allied Healthcare Products, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
USA
Britain
Israel
